title: State-of-the-art human gene therapy: part I. Gene delivery technologies.
abstract: Safe and effective gene delivery is a prerequisite for successful gene therapy. In the early age of human gene therapy, setbacks due to problematic gene delivery vehicles plagued the exciting therapeutic outcome. However, gene delivery technologies rapidly evolved ever since. With the advancement of gene delivery techniques, gene therapy clinical trials surged during the past decade. As the first gene therapy product (Glybera) has obtained regulatory approval and reached clinic, human gene therapy finally realized the promise that genes can be medicines. The diverse gene delivery techniques available today have laid the foundation for gene therapy applications in treating a wide range of human diseases. Some of the most urgent unmet medical needs, such as cancer and pandemic infectious diseases, have been tackled by gene therapy strategies with promising results. Furthermore, combining gene transfer with other breakthroughs in biomedical research and novel biotechnologies opened new avenues for gene therapy. Such innovative therapeutic strategies are unthinkable until now, and are expected to be revolutionary. In part I of this review, we introduced recent development of non-viral and viral gene delivery technology platforms. As cell-based gene therapy blossomed, we also summarized the diverse types of cells and vectors employed in ex vivo gene transfer. Finally, challenges in current gene delivery technologies for human use were discussed.
authors.affiliation: Gene Therapy Center, University of Massachusetts School of Medicine, 368 Plantation St., AS6-2011, Worcester, MA 01605, USA.
authors.forename: Dan
authors.initials: D
authors.lastname: Wang
authors.forename: Guangping
authors.initials: G
authors.lastname: Gao
mesh_terms: D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans
references.citation: Cancer Gene Ther. 2013 Feb;20(2):70-6
references.pmid: 23306610
references.citation: Mol Ther. 2013 Nov;21(11):1976-81
references.pmid: 24201212
references.citation: Discov Med. 2013 Dec;16(90):261-6
references.pmid: 24333405
references.citation: Nat Methods. 2013 Oct;10(10):957-63
references.pmid: 24076990
references.citation: Gene Ther. 2009 Feb;16(2):165-71
references.pmid: 19129858
references.citation: J Biomed Sci. 2013 Dec 09;20:92
references.pmid: 24320156
references.citation: Nat Rev Genet. 2011 May;12(5):301-15
references.pmid: 21445084
references.citation: Nat Med. 2006 Mar;12(3):348-53
references.pmid: 16491086
references.citation: Mol Ther. 2012 Apr;20(4):697-8
references.pmid: 22472980
references.citation: Front Immunol. 2013 Sep 27;4:304
references.pmid: 24098300
references.citation: Nat Immunol. 2006 Jan;7(1):49-56
references.pmid: 16341217
references.citation: Mol Ther. 2011 Aug;19(8):1440-8
references.pmid: 21610699
references.citation: Nat Biotechnol. 2012 Jul 10;30(7):658-70
references.pmid: 22781695
references.citation: Hum Mol Genet. 2011 Apr 15;20(R1):R2-6
references.pmid: 21531790
references.citation: N Engl J Med. 2009 Jan 29;360(5):447-58
references.pmid: 19179314
references.citation: Nat Biotechnol. 2009 Jan;27(1):59-65
references.pmid: 19098898
references.citation: Nature. 2011 Nov 30;481(7379):81-4
references.pmid: 22139420
references.citation: Nat Biotechnol. 2013 Jul;31(7):647-52
references.pmid: 23728362
references.citation: Sci Transl Med. 2012 Jan 4;4(115):115ra1
references.pmid: 22218690
references.citation: Nat Med. 2013 Jul;19(7):889-91
references.pmid: 23770691
references.citation: Mol Ther. 2009 Jul;17(7):1187-96
references.pmid: 19367261
references.citation: Transl Res. 2013 Apr;161(4):265-83
references.pmid: 23313630
references.citation: Curr Pharm Biotechnol. 2013;14(1):46-60
references.pmid: 23437936
references.citation: Clin Immunol. 2014 Jan;150(1):51-63
references.pmid: 24333533
references.citation: Cell Stem Cell. 2010 Oct 8;7(4):429-30
references.pmid: 20887948
references.citation: Biochem J. 2012 May 1;443(3):603-18
references.pmid: 22507128
references.citation: Dev Growth Differ. 2014 Jan;56(1):63-77
references.pmid: 24329887
references.citation: Methods Enzymol. 2012;507:109-24
references.pmid: 22365771
references.citation: Nat Immunol. 2013 Jan;14(1):1-5
references.pmid: 23238748
references.citation: Open Virol J. 2010 Jun 18;4:123-56
references.pmid: 20835362
references.citation: Mol Ther. 2009 Aug;17(8):1333-9
references.pmid: 19513019
references.citation: Nat Rev Microbiol. 2014 Jan;12(1):23-34
references.pmid: 24292552
references.citation: Methods Mol Biol. 2009;542:87-104
references.pmid: 19565897
references.citation: Mol Ther. 2014 Jul;22(7):1299-1309
references.pmid: 24781136
references.citation: J Pain Res. 2014 Jan 20;7:71-9
references.pmid: 24470772
references.citation: Expert Opin Drug Deliv. 2014 Mar;11(3):345-364
references.pmid: 24386892
references.citation: Blood. 2013 Jul 4;122(1):23-36
references.pmid: 23596044
references.citation: Nat Biotechnol. 2007 Nov;25(11):1298-306
references.pmid: 17965707
references.citation: New Microbiol. 2013 Jan;36(1):1-22
references.pmid: 23435812
references.citation: Theranostics. 2014 Jan 15;4(3):240-55
references.pmid: 24505233
references.citation: Nature. 2014 Feb 20;506(7488):382-6
references.pmid: 24390344
references.citation: J Clin Invest. 2009 Jun;119(6):1688-95
references.pmid: 19436115
references.citation: Mol Ther. 2013 May;21(5):954-63
references.pmid: 23459514
references.citation: Methods Mol Biol. 2011;737:89-116
references.pmid: 21590394
references.citation: Science. 2009 Nov 6;326(5954):818-23
references.pmid: 19892975
references.citation: Discov Med. 2013 Feb;15(81):111-9
references.pmid: 23449113
references.citation: Discov Med. 2014 Apr;17(94):207-15
references.pmid: 24759625
references.citation: Nat Biotechnol. 2010 Dec;28(12):1287-9
references.pmid: 21102455
references.citation: Nat Med. 2009 Aug;15(8):901-6
references.pmid: 19448633
references.citation: Curr Gene Ther. 2005 Jun;5(3):285-97
references.pmid: 15975006
references.citation: Gene. 2013 Aug 10;525(2):229-38
references.pmid: 23566848
references.citation: Methods Mol Biol. 2014;1144:63-79
references.pmid: 24671677
references.citation: Nat Rev Genet. 2011 May;12(5):341-55
references.pmid: 21499295
references.citation: J Control Release. 2012 Jul 20;161(2):377-88
references.pmid: 22516095
references.citation: Curr Gene Ther. 2011 Oct;11(5):341-9
references.pmid: 21888621
references.citation: Immunol Rev. 2014 Jan;257(1):181-90
references.pmid: 24329797
references.citation: Discov Med. 2010 Feb;9(45):105-11
references.pmid: 20193635
references.citation: Development. 2013 Jun;140(12):2457-61
references.pmid: 23715538
references.citation: Blood. 2010 Nov 18;116(20):4099-102
references.pmid: 20668228
references.citation: Nat Med. 2012 May;18(5):807-815
references.pmid: 22466705
references.citation: Nat Biotechnol. 2011 Jan;29(1):73-8
references.pmid: 21151124
references.citation: J Virol. 1998 Dec;72(12):9873-80
references.pmid: 9811723
references.citation: Mol Ther. 2008 Jul;16(7):1252-1260
references.pmid: 28178482
references.citation: Nat Rev Genet. 2011 May;12(5):316-28
references.pmid: 21468099
references.citation: Cold Spring Harb Protoc. 2020 Aug 3;2020(8):095513
references.pmid: 32457039
references.citation: Mol Ther. 2013 Jun;21(6):1259-69
references.pmid: 23587921
references.citation: Nat Rev Clin Oncol. 2013 May;10(5):267-76
references.pmid: 23546520
references.citation: N Engl J Med. 2010 Jul 22;363(4):355-64
references.pmid: 20660403
references.citation: Gene. 2013 Aug 10;525(2):162-9
references.pmid: 23618815
references.citation: Cancer Res. 2010 Jun 1;70(11):4297-309
references.pmid: 20484030
references.citation: Expert Opin Biol Ther. 2011 Sep;11(9):1177-91
references.pmid: 21548848
references.citation: Expert Opin Biol Ther. 2013 Jul;13(7):987-1011
references.pmid: 23590247
references.citation: Discov Med. 2013 Jun;15(85):379-89
references.pmid: 23819952
references.citation: Nature. 1999 Oct 7;401(6753):517-8
references.pmid: 10524611